We could not find any results for:
Make sure your spelling is correct or try broadening your search.
This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...
TORONTO, Canada -- November 5, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that...
TORONTO, Ontario, CANADA -- October 16, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF...
TORONTO, Canada -- June 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company...
TORONTO, Canada -- May 8, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...
TORONTO, Canada -- April 24, 2020 -- InvestorsHub NewsWire -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company...
Arch Biopartners Hires d3 Medicine to Develop a Human Trial for Brain Tumor Targeting Technology TORONTO, ONTARIO--(Marketwired - May 29, 2014) - Arch Biopartners Inc (Arch) or (the Company...
Arch Biopartners Appoints Claude Allary to Board of Directors TORONTO, ONTARIO--(Marketwired - Apr 17, 2014) - Arch Biopartners Inc ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced...
Arch Biopartners Enters Option to License University of Cincinnati Patent for Treating Bacterial Respiratory Infections TORONTO, ONTARIO--(Marketwired - Mar 28, 2014) - Arch Biopartners Inc...
Arch Biopartners Completes Private Placement TORONTO, ONTARIO--(Marketwired - Mar 25, 2014) - Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTCBB:FOIFF) announced today it has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.08 | 6.15384615385 | 1.3 | 1.38 | 1.248116 | 8825 | 1.30173626 | CS |
4 | 0.008 | 0.583090379009 | 1.372 | 1.385 | 1.1 | 12822 | 1.2471342 | CS |
12 | 0.0499 | 3.75159762424 | 1.3301 | 1.5225 | 1.1 | 11518 | 1.35566604 | CS |
26 | 0.16 | 13.1147540984 | 1.22 | 1.5225 | 0.8925 | 9526 | 1.27732955 | CS |
52 | 0.288 | 26.3736263736 | 1.092 | 1.88 | 0.8925 | 13376 | 1.36140171 | CS |
156 | -1.42 | -50.7142857143 | 2.8 | 3.38 | 0.72 | 12833 | 1.49908925 | CS |
260 | 0.635 | 85.2348993289 | 0.745 | 4.13 | 0.525 | 13237 | 1.5206613 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions